Mixtard 30 suspension for injection

Država: Armenija

Jezik: engleski

Izvor: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktivni sastojci:

insulin human (recombinant DNA)

Dostupno od:

Novo Nordisk A/S

ATC koda:

A10AD01

INN (International ime):

insulin human (recombinant DNA)

Doziranje:

100IU/ml

Farmaceutski oblik:

suspension for injection

Jedinice u paketu:

glass vial 10ml

Tip recepta:

Prescription

Status autorizacije:

Registered

Datum autorizacije:

2019-06-13

Uputa o lijeku

Mixtard
®
30 vial 100 IU/ml Professional leaflet STF-Jul-2019_site
Denmark_8-0191-00-061-1
Based on: 20190301_EN_06068_06242_MIXT_31-1
1
100 IU/ml
MIXTARD® 30
Suspension for injection in vial.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Insulin human, rDNA (produced by recombinant DNA technology in
_Saccharomyces cerevisiae_).
1 ml contains 100 IU of insulin human.
1 vial contains 10 ml equivalent to 1,000 IU.
One IU (International Unit) corresponds to 0.035 mg of anhydrous human
insulin.
Mixtard® is a mixture of dissolved insulin and isophane (NPH)
insulin.
Mixtard® 30 consists of 30% dissolved insulin and 70% isophane
insulin.
PHARMACEUTICAL FORM
Suspension for injection in vial.
Cloudy, white, aqueous suspension.
THERAPEUTIC INDICATIONS
Treatment of diabetes mellitus.
POSOLOGY AND METHOD OF ADMINISTRATION
Mixtard® is a dual-acting insulin. It is a biphasic formulation
containing both fast-acting and long-acting
insulin. Premixed insulin products are usually given once or twice
daily when a rapid initial effect together
with a more prolonged effect is desired.
DOSAGE
Dosage is individual and determined in accordance with the needs of
the patient. The individual insulin
requirement is usually between 0.3 and 1.0 IU/kg/day. The daily
insulin requirement may be higher in
patients with insulin resistance (e.g. during puberty or due to
obesity) and lower in patients with residual,
endogenous insulin production.
An injection should be followed within 30 minutes by a meal or snack
containing carbohydrates.
DOSAGE ADJUSTMENT
Concomitant illness, especially infections and feverish conditions,
usually increases the patient's insulin
requirement. Concomitant diseases in the kidney, liver or affecting
the adrenal, pituitary or thyroid gland can
require changes in the insulin dose. Adjustment of dosage may also be
necessary if patients change physical
activity or their usual diet. Dosage adjustment may be necessary when
transferring patients from one insulin
preparation to another.
ADMINISTRATION
For subcutaneous use. Ins